Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT03899610

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) — KGOG3046  

Ovarian Cancer Stage IV Clinical Trial

Official title:
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

Clinical Trial Summary

The primary objective of this trial is to evaluate the synergistic effects of durvalumab and tremelimumab plus chemotherapy in advanced-stage ovarian cancer.

Ovarian cancer is the deadliest gynecologic cancer. The current standard therapy is surgical cytoreduction followed by taxane-platinum combination chemotherapy. However, most patients with advanced-stage ovarian cancer will experience a relapse of disease. Therefore, there is an urgent need to improve outcomes of patients with this aggressive cancer.

Research hypothesis: Adding durvalumab and tremelimumab to current neoadjuvant chemotherapy (front-line therapy) in advanced-stage ovarian cancer can increase response rate and improve patient's outcome such as progression-free survival and overall survival with minimal effects on safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03899610
Study type Interventional
Source Yonsei University
Contact Jung-Yun Lee, MD., Ph.D
Phone 82-2-2228-2230
Email jungyunlee@yuhs.ac
Status Recruiting
Phase Phase 2
Start date July 4, 2019
Completion date May 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT00945191 - Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer Phase 2
Recruiting NCT03579394 - Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT04701645 - Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Phase 1
Recruiting NCT03126812 - Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer Phase 1/Phase 2
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Recruiting NCT03922776 - Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer N/A
Completed NCT03085238 - Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer N/A
Recruiting NCT04938583 - Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06017557 - Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) N/A
Suspended NCT05479045 - A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients Phase 2
Completed NCT05005650 - Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
Recruiting NCT04789694 - Prehabilitation in Gynaecological Cancer Patients Phase 3
Not yet recruiting NCT05187208 - PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Phase 4
Recruiting NCT06272240 - Tumor Microenvironment in Ovarian Cancer
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Active, not recruiting NCT03275506 - PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . Phase 2
Recruiting NCT06290193 - Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery Phase 2
Completed NCT02258165 - Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Recruiting NCT03693248 - Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Phase 3